Related Experiment Video
Updated: Feb 3, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
The Safety of an Adjuvanted Autologous Cancer Vaccine Platform in Canine Cancer Patients
Chris Weir1, Annika Oksa2, Jennifer Millar3
1Northern Blood Research Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital and the Sydney Medical School, University of Sydney, Sydney NSW 2065, Australia. chris.weir@sydney.edu.au.
Abstract:
Canine cancer rates are similar to humans, though the therapeutic options might be limited. Inducing a patient's own immune system to have an anti-tumor response is an attractive approach to cancer therapy. In this safety study, autologous tumor vaccines produced specifically for each canine patient were combined with Advax™, a novel non-inflammatory immunomodulator and vaccine adjuvant and were tested for safety in a diverse range of patient presentations alone or in combination with other treatments. Canine patients had their tumor biopsied, debulked or resected and the tumor antigens were processed into an autologous vaccine formulated with Advax™ adjuvant with or without rhizavidin as an additional immune stimulant. Patients treated early in the trial received two intramuscular (IM) doses, 2 weeks apart. As the study progressed and no issues of safety were observed, the protocol was changed to weekly vaccinations for 4 weeks followed by monthly booster shots. Over the 150 I.M injections delivered to date, the vaccine was found to be very safe and no significant adverse reactions were observed. These results justify ongoing development and future controlled studies of this autologous vaccine approach.
Insights
This study found that autologous tumor vaccines combined with Advax™ adjuvant are safe for canine cancer patients. The novel cancer therapy showed no significant adverse reactions in over 150 injections, supporting further research.
Area of Science:
- Veterinary Oncology
- Immunotherapy
- Cancer Vaccines
Background:
- Canine cancer incidence parallels human rates, yet treatment options remain limited.
- Harnessing the patient's immune system for anti-tumor responses presents a promising therapeutic avenue.
- Autologous tumor vaccines offer a personalized approach to cancer treatment.
Purpose of the Study:
- To evaluate the safety and tolerability of autologous tumor vaccines formulated with Advax™ adjuvant in canine patients.
- To assess the feasibility of combining this novel vaccine with other cancer treatments.
- To establish a foundation for future efficacy studies.
Main Methods:
- Tumor samples were obtained from canine patients via biopsy, debulking, or resection.
- Tumor antigens were processed into personalized autologous vaccines.
- Vaccines were formulated with Advax™ adjuvant, with or without rhizavidin, and administered via intramuscular injection.
- Vaccination schedules evolved from initial bi-weekly doses to weekly vaccinations followed by monthly boosters.
Main Results:
- Over 150 intramuscular injections were administered across a diverse patient population.
- The autologous tumor vaccine combined with Advax™ adjuvant demonstrated a strong safety profile.
- No significant adverse reactions were observed during the study.
- The treatment was well-tolerated alone or in combination with other therapies.
Conclusions:
- Autologous tumor vaccines formulated with Advax™ adjuvant are safe and well-tolerated in canine cancer patients.
- These findings support the continued development of this personalized immunotherapy approach.
- Further controlled studies are warranted to investigate the efficacy of this treatment strategy.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

